AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19327226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program intervention (6-week program, weekly sessions lasting 1 hour each)
Number of subjects: 58
Study 19327226 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program intervention
Number of subjects: 58
Study 19327226 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 58
Study 17449497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin to maintain blood glucose <10 mmol/l
Number of subjects: 43
Study 17449497 — intervention group
Group type: COMPARATOR
Intervention: 200 g/day of glucose infusion (control group)
Number of subjects: 43
Study 17449497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin
Number of subjects: 43
Study 17449497 — intervention group
Group type: COMPARATOR
Intervention: Control group (200 g/day of glucose infusion)
Number of subjects: 43
Study 14718403 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized adrenomedullin (10 microg/kg body weight)
Number of subjects: 11
Study 14718403 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 11
Study 11477965 — intervention group
Group type: EXPERIMENTAL
Intervention: Vi polysaccharide vaccine (30 micrograms)
Number of subjects: 131271
Study 11477965 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 131271
Study 9866002 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 60
Study 9866002 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 60
Study 7704991 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (41 nmol/min) with edrophonium (0.5 mumol/min intra-arterially)
Number of subjects: 0
Study 7704991 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (16 and 41 nmol/min)
Number of subjects: 0
Study 7704991 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (41 nmol/min)
Number of subjects: 0
Study 7704991 — intervention group
Group type: COMPARATOR
Intervention: Methacholine (5 nmol/min)
Number of subjects: 0
Study 2483018 — intervention group
Group type: COMPARATOR
Intervention: Conventional dextran alone
Number of subjects: 150
Study 2483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran with additional graded compression stockings
Number of subjects: 150
Study 2483018 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative administration of dextran
Number of subjects: 150
Study 1107969 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizotifen
Number of subjects: 32
Study 1107969 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 32
Study 1107969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30694077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oestradiol (4 mg/d) plus vaginal progesterone (90 mg, 2×1/day)
Number of subjects: 150
Study 30694077 — intervention group
Group type: COMPARATOR
Intervention: Vaginal progesterone (90 mg, 2×1/day) alone
Number of subjects: 150
Study 30849606 — intervention group
Group type: EXPERIMENTAL
Intervention: Instability training on unstable surfaces
Number of subjects: 43
Study 30849606 — intervention group
Group type: COMPARATOR
Intervention: Balance training on stable ground (Control)
Number of subjects: 43
Study 28976605 — intervention group
Group type: COMPARATOR
Intervention: DHA supplementation for 16 weeks
Number of subjects: 10
Study 28976605 — intervention group
Group type: COMPARATOR
Intervention: DHA supplementation for 40 weeks
Number of subjects: 10
Study 25499165 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (maintaining haemoglobin level at 100 g/L or higher)
Number of subjects: 2016
Study 25499165 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion when haemoglobin level lower than 80 g/L or symptoms of anaemia)
Number of subjects: 2016
Study 22766102 — intervention group
Group type: EXPERIMENTAL
Intervention: Globus pallidus deep brain stimulation (GP DBS)
Number of subjects: 0
Study 22766102 — intervention group
Group type: COMPARATOR
Intervention: Stimulation location within the globus pallidus
Number of subjects: 0
Study 21247662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor Healing Ointment (AHO)
Number of subjects: 30
Study 21247662 — intervention group
Group type: COMPARATOR
Intervention: Polysporin (Poly/Bac)
Number of subjects: 30
Study 19592630 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and metformin
Number of subjects: 58
Study 19592630 — intervention group
Group type: COMPARATOR
Intervention: Metformin, pioglitazone, and glyburide (oral group)
Number of subjects: 58
Study 17242671 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy (platin-based chemotherapy)
Number of subjects: 0
Study 17242671 — intervention group
Group type: COMPARATOR
Intervention: Platin-based chemotherapy
Number of subjects: 0
Study 17242671 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified schedules or attenuated dose of platin-containing chemotherapy
Number of subjects: 0
Study 16422974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0
Study 16422974 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 0
Study 16422974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11194113 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS, 20 g x d(‐1) of Cr)
Number of subjects: 0
Study 11194113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P1)
Number of subjects: 0
Study 11194113 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS)
Number of subjects: 0
Study 11194113 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented)
Number of subjects: 0
Study 9481725 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile AN69 (PAN)
Number of subjects: 5
Study 9481725 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan (CUP)
Number of subjects: 5
Study 2001016 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental infusion
Number of subjects: 300
Study 2001016 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 300
Study 6390450 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II studies screening for activity in patients with measurable advanced disease
Number of subjects: 0
Study 6390450 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase III studies aimed at controlling the recurrence rate of superficial bladder tumors
Number of subjects: 0
Study 31462732 — intervention group
Group type: EXPERIMENTAL
Intervention: auto/alloSCT
Number of subjects: 199
Study 31462732 — intervention group
Group type: COMPARATOR
Intervention: tandem autoSCT
Number of subjects: 199
Study 31462732 — intervention group
Group type: EXPERIMENTAL
Intervention: auto/alloSCT (in patients with both del13q and del17p)
Number of subjects: 199
Study 31462732 — intervention group
Group type: COMPARATOR
Intervention: tandem autoSCT (in patients with both del13q and del17p)
Number of subjects: 199
Study 29353006 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained participants
Number of subjects: 102
Study 29353006 — intervention group
Group type: COMPARATOR
Intervention: Untrained controls (overweight and obesity)
Number of subjects: 102
Study 29353006 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 102
Study 27188901 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g · day(‐1))
Number of subjects: 13
Study 23021204 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223 (50 kBq/kg, 4 injections every 4 weeks)
Number of subjects: 64
Study 23021204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23021204 — intervention group
Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 64
Study 23021204 — intervention group
Group type: COMPARATOR
Intervention: Radium-223 and Placebo
Number of subjects: 64
Study 21346020 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for insomnia
Number of subjects: 40
Study 21346020 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene (SH)
Number of subjects: 40
Study 19724041 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 352
Study 19724041 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 352
Study 17023087 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction group with on‐screen, visual display of predicted glycemia and predicted risks of hypoglycemia
Number of subjects: 22
Study 17023087 — intervention group
Group type: COMPARATOR
Intervention: Control group without glycemic predictions
Number of subjects: 22
Study 15240119 — intervention group
Group type: EXPERIMENTAL
Intervention: IA‐2A positive patients
Number of subjects: 0
Study 15240119 — intervention group
Group type: EXPERIMENTAL
Intervention: GADA positive patients
Number of subjects: 0
Study 15240119 — intervention group
Group type: EXPERIMENTAL
Intervention: TopIIA and GADA
Number of subjects: 0
Study 11434648 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-enriched formula (6.3 g/L)
Number of subjects: 37
Study 11434648 — intervention group
Group type: COMPARATOR
Intervention: Control formula (isocaloric and isonitrogenous)
Number of subjects: 37
Study 10492101 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine exteriorisation during caesarean section
Number of subjects: 288
Study 10492101 — intervention group
Group type: COMPARATOR
Intervention: Suture of the uterus in the abdomen (Control)
Number of subjects: 288
Study 7851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal fibronectin (fFN) in cervicovaginal secretions
Number of subjects: 78
Study 7851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic treatment
Number of subjects: 78
Study 7851710 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm rupture of membranes (PROM)
Number of subjects: 78
Study 7851710 — intervention group
Group type: COMPARATOR
Intervention: Control group (negative for fFN)
Number of subjects: 78
Study 2572261 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol treatment
Number of subjects: 705
Study 2572261 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 705
Study 61664 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 39
Study 31961963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil + Mirabegron (5 mg/50 mg/day)
Number of subjects: 176
Study 31961963 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil (5 mg/day)
Number of subjects: 176
Study 30562897 — intervention group
Group type: EXPERIMENTAL
Intervention: FusPbx (MRI-ultrasound fusion targeted biopsy)
Number of subjects: 41
Study 30562897 — intervention group
Group type: COMPARATOR
Intervention: USPbx (randomized 12-core transrectal ultrasound guided biopsy)
Number of subjects: 41
Study 28448250 — intervention group
Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) program
Number of subjects: 201
Study 28448250 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (site screener, interest forms, marketing materials, site liaisons)
Number of subjects: 201
Study 25466951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein low-carbohydrate (HPLC) diet (30% protein, 35% carbohydrate, 35% fat)
Number of subjects: 32
Study 25466951 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate low-protein (HCLP) diet (5% protein, 60% carbohydrate, 35% fat)
Number of subjects: 32
Study 25466951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein low-carbohydrate (HPLC) diet
Number of subjects: 32
Study 25466951 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate low-protein (HCLP) diet
Number of subjects: 32
Study 23684374 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular block (IB)
Number of subjects: 82
Study 23684374 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided axillary block (AB)
Number of subjects: 82
Study 20835873 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal granisetron (GTDS), one patch for 7 days
Number of subjects: 641
Study 20835873 — intervention group
Group type: COMPARATOR
Intervention: Oral granisetron, 2 mg/day for 3-5 days
Number of subjects: 641
Study 19234005 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile video telephony (VT) guidance
Number of subjects: 0
Study 19234005 — intervention group
Group type: COMPARATOR
Intervention: Non-video telephony (non-VT) guidance
Number of subjects: 0
Study 16102936 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic exercise
Number of subjects: 60
Study 16102936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 60
Study 16102936 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 12601675 — intervention group
Group type: EXPERIMENTAL
Intervention: WS(R) 1340 (90 mg peppermint oil)
Number of subjects: 0
Study 12601675 — intervention group
Group type: EXPERIMENTAL
Intervention: WS(R) 1520 (50 mg caraway oil)
Number of subjects: 0
Study 12601675 — intervention group
Group type: EXPERIMENTAL
Intervention: WS(R) 1340
Number of subjects: 0
Study 12601675 — intervention group
Group type: EXPERIMENTAL
Intervention: WS(R) 1520
Number of subjects: 0
Study 12601675 — intervention group
Group type: COMPARATOR
Intervention: Hydrophobic phase (control)
Number of subjects: 0
Study 10864082 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand exercise (intermittent squeezing of a hand-sized ball) during contrast material delivery
Number of subjects: 80
Study 10864082 — intervention group
Group type: COMPARATOR
Intervention: No hand exercise (control group)
Number of subjects: 80
Study 9173811 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin
Number of subjects: 40
Study 9173811 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch (HAES-steril)
Number of subjects: 40
Study 7968752 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 776
Study 7968752 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (tPA)
Number of subjects: 776
Study 7968752 — intervention group
Group type: EXPERIMENTAL
Intervention: Time trade-off question
Number of subjects: 776
Study 3295037 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate gluconate (40 mmol of elemental calcium/day)
Number of subjects: 18
Study 3295037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30077640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemafibrate (0.4 mg/d, twice daily for 4 weeks)
Number of subjects: 33
Study 30077640 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 33
Study 28506475 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine perfused simulator (PL)
Number of subjects: 0
Study 28506475 — intervention group
Group type: COMPARATOR
Intervention: Rubber tubing model (Control)
Number of subjects: 0
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with established agreements on the transition procedure
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with median serum creatinine levels
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with immunosuppression levels
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with increased creatinine levels
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with biopsy proven rejection
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with graft loss due to chronic graft nephropathy
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with adherence to immunosuppression
Number of subjects: 119
Study 26632907 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition care with increased creatinine levels close to transfer
Number of subjects: 119
Study 23286943 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 26
Study 23286943 — intervention group
Group type: COMPARATOR
Intervention: glyburide
Number of subjects: 26
Study 21264453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CsA) 2.5 mg/kg
Number of subjects: 30
Study 21264453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin A (CsA)
Number of subjects: 30
Study 18514525 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial constraint present
Number of subjects: 6
Study 18514525 — intervention group
Group type: COMPARATOR
Intervention: No spatial constraint
Number of subjects: 6
Study 17199455 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (3-month treatment with a 1-month taper)
Number of subjects: 152
Study 17199455 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking (control group)
Number of subjects: 152
Study 12590330 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed in-line suction catheters (CISC) applied for 72 hours
Number of subjects: 23
Study 10868348 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief individual counseling and weekly newsletters (intervention)
Number of subjects: 186
Study 10868348 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 123)
Number of subjects: 186
Study 10868348 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 63)
Number of subjects: 186
Study 9354072 — intervention group
Group type: EXPERIMENTAL
Intervention: Day case adenoidectomy
Number of subjects: 64
Study 9354072 — intervention group
Group type: COMPARATOR
Intervention: In-patient adenoidectomy
Number of subjects: 64
Study 8456052 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal microwave hyperthermia of the prostate
Number of subjects: 54
Study 3935013 — intervention group
Group type: EXPERIMENTAL
Intervention: Education program regarding asthma and asthma medications during four monthly visits
Number of subjects: 31
Study 3935013 — intervention group
Group type: COMPARATOR
Intervention: Noneducation group
Number of subjects: 31
Study 30126103 — intervention group
Group type: EXPERIMENTAL
Intervention: IEPalm
Number of subjects: 85
Study 30126103 — intervention group
Group type: EXPERIMENTAL
Intervention: IEStear
Number of subjects: 85
Study 30126103 — intervention group
Group type: COMPARATOR
Intervention: NatPO
Number of subjects: 85
Study 27040451 — intervention group
Group type: COMPARATOR
Intervention: CABG alone
Number of subjects: 301
Study 27040451 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus mitral-valve repair
Number of subjects: 301
Study 24886555 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face guided self-help
Number of subjects: 51
Study 24886555 — intervention group
Group type: EXPERIMENTAL
Intervention: Email guided self-help
Number of subjects: 51
Study 24886555 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control
Number of subjects: 51
Study 22906794 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (n = 18) - shown detailed PSG data, including graphic data from PSG prior to prescription of CPAP
Number of subjects: 37
Study 22906794 — intervention group
Group type: COMPARATOR
Intervention: Control arm (n = 19) - shown the non‐graphic paper report of the PSG
Number of subjects: 37
Study 22906794 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 37
Study 20189492 — intervention group
Group type: COMPARATOR
Intervention: Investigational hepatitis B vaccine (spHB), 10 microg HBsAg/dose for 10-15 years age group; 20 microg HBsAg/dose for 16-45 years age group, administered in a 0, 1, 6 month schedule.
Number of subjects: 688
Study 20189492 — intervention group
Group type: COMPARATOR
Intervention: Licensed control vaccine (Engerix B), administered in a 0, 1, 6 month schedule.
Number of subjects: 688
Study 18818095 — intervention group
Group type: EXPERIMENTAL
Intervention: PVA particles mixed with ketoprofen
Number of subjects: 80
Study 18818095 — intervention group
Group type: COMPARATOR
Intervention: Bland PVA particles
Number of subjects: 80
Study 15993559 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB questionnaire + formed own implementation intention
Number of subjects: 220
Study 15993559 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB questionnaire + researcher formed implementation intention
Number of subjects: 220
Study 15993559 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB questionnaire
Number of subjects: 220
Study 15993559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study 12946746 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 820
Study 12946746 — intervention group
Group type: COMPARATOR
Intervention: Multivariate logistic regression analysis
Number of subjects: 820
Study 12946746 — intervention group
Group type: COMPARATOR
Intervention: f/t PSA ratio
Number of subjects: 820
Study 12946746 — intervention group
Group type: COMPARATOR
Intervention: PSA-TZ
Number of subjects: 820
Study 12946746 — intervention group
Group type: COMPARATOR
Intervention: PSAD
Number of subjects: 820
Study 12946746 — intervention group
Group type: COMPARATOR
Intervention: Total PSA
Number of subjects: 820
Study 12946746 — intervention group
Group type: EXPERIMENTAL
Intervention: ANN
Number of subjects: 820
Study 12946746 — intervention group
Group type: COMPARATOR
Intervention: Multivariate analysis
Number of subjects: 820
Study 10372701 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment; mean dosage 1.0 U/day for men and 1.9 U/day for women (P < 0.01)
Number of subjects: 33
Study 10372701 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (rhGH) treatment
Number of subjects: 33
Study 8717465 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB with leuprolide and flutamide
Number of subjects: 1300
Study 8717465 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy with flutamide
Number of subjects: 1300
Study 8717465 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy with placebo
Number of subjects: 1300
Study 8717465 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB
Number of subjects: 1300
Study 1941495 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC mouthrinse used as an adjunct to oral hygiene before toothbrushing
Number of subjects: 0